Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04955366 · ClinicalTrials.gov registry record · Phase 2
Abatacept Conversion in Kidney Transplantation
A Phase 2 study of Renal Transplant Recipient, sponsored by Emory University.
- Active
- Registry status
- Phase 2
- Development phase
- 87
- Enrollment target
- 1
- Study location
NCT04955366 is a Phase 2 study of Renal Transplant Recipient that is active but no longer recruiting, run by Emory University. The registered enrollment target is 87 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04955366, a Phase 2 study of Renal Transplant Recipient, is active but no longer recruiting, sponsored by Emory University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 87 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single center, randomized, controlled phase 2b, conversion trial. This protocol has been developed to answer the question: Can patients be safely converted from monthly belatacept IV infusions to abatacept subcutaneous injections without a decrease in kidney function.The primary objective will be the difference in estimated GFR (eGFR) for abatacept and belatacept groups using a monthly repeated measures model between randomization and 12 months.
Conditions Studied
Interventions
- DRUG Abatacept
- DRUG Belatacept
Study Locations (1)
Georgia
- Emory University Hospital (EUH) - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2021-09-22 |
| Est. Completion | 2026-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04955366
The ClinicalTrials.gov registry entry for NCT04955366 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Renal Transplant Recipient appearing as the primary indexed condition, and to 2 interventions - of which Abatacept is the first listed.
NCT04955366 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT04955366 about?
NCT04955366 is a clinical study titled "Abatacept Conversion in Kidney Transplantation". This is a single center, randomized, controlled phase 2b, conversion trial. This protocol has been developed to answer the question: Can patients be safely converted from monthly belatacept IV infusions to abatacept subcutaneous injections without a decrease in kidney function.The primary objective ...
What is the current status of trial NCT04955366?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 87 participants. The study started on 2021-09-22. Estimated completion is 2026-06.
What conditions does trial NCT04955366 study?
This clinical trial studies the following conditions: Renal Transplant Recipient.
What interventions are being tested in trial NCT04955366?
The interventions under investigation include: Abatacept (DRUG), Belatacept (DRUG).
Who is sponsoring clinical trial NCT04955366?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04955366 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Transplant Recipient
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.